Oncotelic Grants N2B Platform Rights for $12.5M

Oncotelic Therapeutics (OTCQB: OTLC) has announced a strategic asset transfer agreement with Lunai Bioworks, Inc., granting worldwide rights to its nose-to-brain (N2B) delivery system IP within the biodefense and Alzheimer’s disease fields. In exchange, Oncotelic will receive $12.5 million in Series B convertible preferred stock. This agreement establishes a dedicated initiative focused on CNS-targeted therapeutics, while supporting Oncotelic’s broader strategy to monetize its portfolio and retain control of core assets. The N2B platform enables intranasal delivery directly to the central nervous system, bypassing the blood-brain barrier to facilitate rapid therapeutic action and targeted neurological engagement. This technology has promising applications in biodefense medical countermeasures and neurodegenerative conditions like Alzheimer's disease.

Under the terms of the agreement, Lunai Bioworks will develop the platform within the specified fields, while Oncotelic retains rights for other indications, including Parkinson’s disease and sexual dysfunction. This allows Oncotelic to leverage its internal expertise in CNS therapeutics and biodefense. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, with a mission to address high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Additionally, Oncotelic leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes.

Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens its position in oncology and rare disease therapeutics. For more details, the full press release is available at https://ibn.fm/IWUpe.